Navigation Links
FDA Panel OKs Antipsychotic Seroquel for Children

The drug, and others like it, have been linked to certain health risks, experts note,,

WEDNESDAY, June 10 (HealthDay News) -- A U.S. Food and Drug Administration advisory panel on Wednesday voted "overwhelmingly" that Seroquel, a powerful antipsychotic drug, be approved to treat schizophrenia in children.

A ruling on Seroquel's use for children with bipolar disorder is also expected Wednesday, as are similar decisions for the antipsychotics Geodon and Zyprexa, the Associated Press reported.

All three are part of the new-generation "atypical" antipsychotics, currently approved for adult use. The medications have been prescribed "off-label" by many doctors for years to treat schizophrenia and bipolar disorder in children ages 10 to 17, despite possible serious side effects, including diabetes and heart woes.

Seroquel is made by drug maker AstraZeneca. Pharmaceutical giant Lilly is seeking the same approvals for Zyprexa. And drug maker Pfizer wants approval to market Geodon to treat bipolar disorder in patients 10 to 17 years old.

There is a pressing need for effective antipsychotics for children, one expert noted.

"Schizophrenia and bipolar disorder are very real illnesses, which collectively affect between 1 percent and 3 percent of all young people," noted Dr. David Fassler, a clinical professor of psychiatry at the University of Vermont College of Medicine, who testified before the panel Tuesday. "Without treatment, children have problems at school, at home, and with their friends. They're also at increased risk of accidents, hospitalization, and death at an early age from multiple causes, including suicide."

And yet safety concerns plague many of these drugs. In 2004, the FDA ordered AstraZeneca to add a special "black box" warning to Seroquel's packaging, outlining increased risks of hyperglycemia, high blood pressure and diabetes associated with use of the drug. Also, older patients with dementia-related psychosis treated with Seroquel are at an increased risk of death, according to the FDA.

And in a unanimous vote in early April, an FDA advisory panel determined that Seroquel should not be approved as first-line therapy for adult depression, because of continued questions about its safety profile -- most notably, a link to higher risk for sudden cardiac death. However, the drug was approved for use in patients for whom other antidepressants didn't work.

The family of atypical antipsychotics has other well-documented potential side effects, including weight gain and high blood sugar, which can increase the risk of diabetes, as well as rapid heart beat, difficulty sleeping and trouble concentrating.

Ronald T. Brown, dean and professor of public health at Temple University Health Sciences Center, testified before the panel Tuesday. Speaking to HealthDay, he said there's still too little known about the efficacy and side effects of these medications in children for the FDA to approve their use in kids.

"The problems are what we don't know rather than what we do know," Brown said. "We don't know anything about the long-term effects of these medications; they have only been through a six-week trial."

"I am not convinced about the long-term safety of these drugs," he added.

"Particularly with children, when you don't know, I don't think you should approve it," Brown said. "In this country, we are very over-zealous to approve drugs. I think we need to be more conservative, particularly because this is a pediatric population."

Brown believes off-label use may be safe, because it is done for particular patients, with the family's consent. "That's a lot different than saying this drug has been approved for children and adolescents," he said.

Prior studies have also found that these newer drugs are no more effective than older medications. Their main advantage is that they do not cause the tremors and muscle spasms associated with older agents.

Diana Zuckerman is president of the National Research Center for Women & Families, a Washington, DC advocacy group. She believes much more study is needed before good decisions can be made as to the use of these antipsychotics by youngsters.

According to Zuckerman, the small studies that are out there suggest that, while on these drugs, "between 20 to 30 percent of kids were gaining weight, heart rates were increased, many of the kids were so knocked out ('sedated') that they could barely function."

Overall, the trials submitted to the FDA panel were small, Zuckerman added, noting there were "usually less than 100 at a specific dosage."

"If you want to prove that the benefits outweigh the risks," she said, "it is necessary to study thousands of kids for at least a year in double-blind studies, preferably longer. These studies don't come close to doing that."

Fassler took a more measured view.

"None of these medications should be used without careful consideration of the risks and benefits," he said. "Children and adolescents taking these medications should be monitored closely for evidence of significant side effects or adverse reactions. Nonetheless, when used appropriately, these medications can be a helpful and effective component of treatment for children and adolescents with schizophrenia or bipolar disorder."

In any case, drugs should never be viewed as the only therapeutic option open to young patients, according to Fassler.

"Medication, including the atypical antipsychotics, can be helpful to control some of the signs and symptoms associated with these disorders, but medication alone is rarely an adequate or sufficient intervention. It should only be used as part of a comprehensive treatment plan, individualized to the needs of the child and family," Fassler said.

Although the FDA isn't required to follow advisory committee recommendations, it usually does.

More information

For more information on atypical antipsychotics, visit the U.S. Food and Drug Administration .

SOURCES: David Fassler, M.D., clinical professor of psychiatry, University of Vermont College of Medicine, Burlington; Diana Zuckerman, Ph.D., president, National Research Center for Women & Families, Washington, DC; Ronald T. Brown, Ph.D., dean and professor of public health, Temple University Health Sciences Center, Philadelphia; Associated Press

Copyright©2009 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Virginia Tech Review Panel Calls For Reform of Mental Health Treatment Law
2. CryoCor Invited to Participate in FDA Advisory Panel Meeting on Atrial Fibrillation
3. Patient Safety Authority Board of Directors Names Infection Advisory Panel
4. Partners Rx Chief Pharmacy Officer, Richard Bullard on Panel Discussion at the Fall 2007 Managed Markets Summit (MMS) in Phoenix, AZ.
5. Billians HealthDATA GM Speaking on Dreamforce 07 Panel
6. FDA Panel Recommends Approval of SyntheMeds REPEL-CV(R) Adhesion Barrier for Pediatric Patients
7. Abaxis Announces New Waived Kidney Check Panel Exclusively for Imaging and Radiology Centers
8. Health Courts Critic to be Featured Speaker at Wyoming Patient Safety Panel
9. FDA Panel Mulls Ban on Kids Cold Medicines
10. FDA Panel Weighs Ban on Kids Cold Medicines
11. FDA Panel Recommends Ban on Cold Medicines for Kids
Post Your Comments:
Related Image:
FDA Panel OKs Antipsychotic Seroquel for Children
(Date:6/26/2016)... (PRWEB) , ... June 26, 2016 , ... Pixel Film ... Pro X. , "Film editors can give their videos a whole new perspective by ... Austin - CEO of Pixel Film Studios. , ProSlice Levels contains over 30 ...
(Date:6/26/2016)... ... June 26, 2016 , ... Many ... been diagnosed with endometriosis. These women need a treatment plan to not only ... approach that can help for preservation of fertility and ultimately achieving a pregnancy. ...
(Date:6/25/2016)... ... ... Bruton Memorial Library on June 21 due to a possible lice infestation, as reported by ... lice: the parasite’s ability to live away from a human host, and to infest common ... the event that lice have simply gotten out of control. , As lice are a ...
(Date:6/25/2016)... Beach, CA (PRWEB) , ... June 25, 2016 , ... ... UCLA with Magna Cum Laude and his M.D from the David Geffen School of ... Diego and returned to Los Angeles to complete his fellowship in hematology/oncology at the ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits of moderation, whether ... latter, setting the bar too high can result in disappointment, perhaps even self-loathing. However, ... their goal. , Research from reveals that behind the tendency ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... 24, 2016  Global Blood Therapeutics, Inc. (GBT) (NASDAQ: ... novel therapeutics for the treatment of grievous blood-based ... closing of its previously announced underwritten public offering ... public offering price of $18.75 per share. All ... by GBT. GBT estimates net proceeds from the ...
(Date:6/24/2016)... 2016 The Academy of Managed Care Pharmacy ... that would allow biopharmaceutical companies to more easily share ... formulary and coverage decisions, a move that addresses the ... The recommendations address restrictions in the sharing ... drug label, a prohibition that hinders decision makers from ...
(Date:6/24/2016)... According to a new market ... Needles, Safety Pen Needles), Needle Length (4mm, 5mm, 6mm, ... of Purchase (Retail, Non-Retail) - Trends & Global Forecasts ... market for the forecast period of 2016 to 2021. ... by 2021 from USD 1.65 Billion in 2016, growing ...
Breaking Medicine Technology: